Skip to main content
. 2019 Dec 23;2019:5821589. doi: 10.1155/2019/5821589

Figure 4.

Figure 4

Effects of MT-1303 and FK506 on the development of proteinuria in NZBWF1 mice. MT-1303 and FK506 were orally administered to NZBWF1 mice daily from 30 to 40 weeks of age. (a) Percent survival in each group was shown over the study period. (b, c) Urinary protein concentrations were measured using the Bradford method once a week and scored on a scale of 0–4. Results are expressed as the mean ± S.E.M. of 12 mice. Statistical differences were calculated using the Shirley-Williams test by comparison with the control (p < 0.05).